Refractory Acute Myeloid Leukemia (AML) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Refractory Acute Myeloid Leukemia (AML) Market Outlook
Thelansis’s “Refractory Acute Myeloid
Leukemia (AML) Market Outlook, Epidemiology, Competitive Landscape, and Market
Forecast Report – 2024 To 2034" covers disease overview, epidemiology,
drug utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Refractory Acute Myeloid Leukemia
(AML) treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Refractory
Acute Myeloid Leukemia (AML) Overview
Refractory
Acute Myeloid Leukemia (AML) affects about 50% of all patients who achieve
remission after initial treatment. With a long-term disease-free survival of
only approximately 30 to 40% after standard chemotherapy and a paucity of
treatment options besides the standard cytarabine and anthracyclines, disease
persistence or recurrence occurs in most patients with AML. Outcomes for
patients with relapsed or refractory AML are poor, with overall survival (OS)
estimated at no more than 10% at three years. The prognosis for relapsed acute
myeloid leukemia (AML) is unfavorable, and managing the disease presents
significant challenges. Among patients who achieve complete remission after
relapse, allogeneic hematopoietic cell transplantation (allo-HCT) remains the
most effective treatment option. Relapse after allo-HCT remains a major
obstacle, with a 1-year post-relapse OS of ~20%. Although several therapeutic
options are available for relapsed AML after transplantation, only a minority
of patients survive long-term.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment